Table 3 Differences in the baseline characteristics between patients with biologic treatment failure and those without.
Treatment failure | Non-failure | P value | |
|---|---|---|---|
Number of patients | 8 | 45 | |
Age, mean (SD) | 39.6 (13.7) | 45.2 (17.6) | 0.401 |
Gender, Male, n (%) | 6 (75.0) | 26 (57.8) | 0.359 |
Disease location, Extensive colitis, n (%) | 4 (50.0) | 38 (84.4) | 0.048 |
Extra-intestinal manifestation, n (%) | 1 (12.5) | 10 (22.2) | > 0.999 |
Biologics, n (%) | |||
IFX | 1 (12.5) | 5 (11.1) | |
ADA | 0 (0.0) | 8 (17.8) | |
GLM | 5 (62.5) | 19 (42.2) | |
VDZ | 1 (12.5) | 6 (13.3) | |
UST | 1 (12.5) | 7 (15.6) | |
Concomitant 5-ASA, n (%) | 7 (87.5) | 35 (77.8) | > 0.999 |
Concomitant thiopurines, n (%) | 2 (25.0) | 11 (24.4) | > 0.999 |
Initial disease activity (PRO2), mean (SD) | 1.88 (0.83) | 1.27 (1.53) | 0.069 |
PRO2-based clinical remission, n (%) | 0 (0.0) | 26 (78.8) | < 0.001 |
Symptomatic remission, n (%) | 4 (50.0) | 43 (95.6) | 0.003 |
Endoscopic healing, n (%) | 0 (100.0) | 33 (73.3) | < 0.001 |
